Dermatitis News

Dupilumab significantly improved atopic dermatitis signs, symptoms and quality of life in Asian, black and white patients, according to a pooled analysis of three phase 3 trials.

The FDA has granted final approval for pimecrolimus cream 1%, a generic form of Elidel, according to an announcement from Glenmark Pharmaceuticals.

Patients with moderate to severe atopic dermatitis had a 20% increase in the long-term risk for atrial fibrillation although the absolute risk remains low, according to findings from a 35-year cohort study.

Baricitinib met the primary endpoint in adults with moderate to severe atopic dermatitis in BREEZE-AD7, the third pivotal phase 3 trial of the BREEZE-AD program, which is expected to be completed later this year.

Methotrexate may be used as a third-line therapy for treating chronic spontaneous urticaria, but it was not superior to placebo added to H1-antihistamines, according to a research letter in the Journal of the American Academy of Dermatology.

A teledermatology program at the Cleveland Clinic resulted in a reduction in visits and diagnostic concordance comparable to previously reported findings, according to results published in Journal of the American Academy of Dermatology.

Dupilumab showed consistent and sustained efficacy in an open-label extension study in adults previously enrolled in 12 parent studies assessing dupilumab in moderate to severe atopic dermatitis.

A resource on new developments in psoriasis in recognition of Psoriasis Action Month was the most popular story of the week at Healio Dermatology.

Children aged 6 to 11 years with severe atopic dermatitis assigned dupilumab and topical corticosteroids significantly improved in measures of overall disease severity, skin clearing, itching and health-related quality of life vs. topical corticosteroids alone in a phase 3 trial.

The American Academy of Dermatology Summer Meeting recently wrapped up in New York.